United States Influenza Vaccine Market is expected to reach more than US$ 2.5 Billion by the year end of 2022

United States Influenza Vaccine Market is expected to reach more than US$ 2.5 Billion by the year end of 2022.
Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccine and introduction of quadrivalent influenza vaccine.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It provides essential insights into United States influenza vaccine market and forecast. It covers vaccination pattern, doses distribution, production and offers a clear view of the regulatory landscape. Additionally, the report includes insight of clinical trials, pipeline and promising vaccines in United States influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.
The report concludes with the profiles of major players in the influenza vaccine market such as Sanofi Pasteur, GSK, Seqirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. The report also entails major drivers and barriers of influenza vaccine market.
Major and Promising Vaccine covered in the report are as follows:
1. Fluzone High–Dose
2. Fluzone Quadrivalent
3. Intradermal (ID) Trivalent
4.Vaxigrip
5. Fluarix Quadrivalent
6. Flulaval Quadrivalent
7. Fluenz Tetra
8.FluMist Quadrivalent
9. Flublok
10. VN–100
11. M–001
12. VAX–2012Q
13. TAK – 850
14. Flucelvax Quadrivalent
15. Afluria Quadrivalent
16. Agrippal
17. Fluad
18. Fluvirin
19. Fluvax
Key Companies Covered in the Report are as follows
1. Sanofi Pasteur
2. GlaxoSmithKline(GSK)
3. Seqirus
4. AstraZenecca
5. Protein Sciences Corporation
6. Novavax
7. Daiichi–Sankyo
8. Mitsubishi Tanabe Pharma
9. BiondVax Pharmaceuticals Ltd
10. VaxInnate
Research Methodology 
DPI Research’s team of researchers and analysts use a variety of research sources for making a report. Most of the data – information and statistics – for our products is gathered using the secondary research by in–house team of researchers. The main objective of DPI Research’s secondary research exercise is to exhaust all sources of published information including websites of government agencies, consumer and trade associations, annual reports and accounts of companies, news articles from well–known publications and online databases like Factiva, OneSource, Thomson, Hoovers, etc. The data thus gathered is send to our team of analysts who verify that data and look for research gaps. These gaps are filled through primary research, that is, our analysts gain information from various agencies, associations and companies using customer surveys, telephonic and email interviews, etc. Finally, all the information collected using secondary and primary research is analysed and synthesized by our analysts and is presented in a report.
Industry information and data for this report has been sourced through numerous channels including publically available information from companies’ and industry association websites. For industry sizing, segmentation and trends, apart from desk research, we have contacted industry experts and executives from various companies.
Market forecasts are done using statistical forecasting techniques based on historic performance. Statistical tools are further supplemented with qualitative parameters like industry expectation, economic drivers, new product development, customer surveys, ongoing research, etc.
All the information gathered was then analysed and synthesized by in–house team of analysts.

Leave Comment

Your email address will not be published. Required fields are marked *